Loading…
for educational and safety purposes
3-MeO-PCP and Methoxetamine both come up in the same conversations; they overlap on Glutamate. 3-MeO-PCP: 3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. Methoxetamine: Methoxetamine (MXE) is an arylcyclohexylamine dissociative developed as a ketamine analog and widely sold as a research chemical before international bans.
3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. It acts principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor and is additionally reported to inhibit monoamine reuptake, giving it a more stimulating and dopaminergic character than ketamine; the closely related analogs 4-MeO-PCP and 3-MeO-PCMo have been shown to engage the mesolimbic dopamine pathway to produce rewarding and reinforcing effects. It is considerably more potent and longer-acting than ketamine, which contributes to a narrow margin between recreational and toxic exposure. The compound has been implicated in numerous non-fatal intoxications and deaths, and its metabolism and analytical detection have been characterized in forensic casework and in silico ADME studies. Because standard phencyclidine immunoassays detect it inconsistently, laboratory confirmation generally relies on chromatographic and mass-spectrometric methods.
Methoxetamine (MXE) is an arylcyclohexylamine dissociative developed as a ketamine analog and widely sold as a research chemical before international bans. It acts as a potent uncompetitive antagonist at the NMDA glutamate receptor, binding the phencyclidine site within the channel pore to produce dissociative, anesthetic, and psychotomimetic effects; unlike ketamine it also engages serotonergic systems, raising cortical and accumbal serotonin and relying partly on 5-HT2 receptors for some of its sensorimotor effects. Its longer duration and greater intensity relative to ketamine, marketed misleadingly as "bladder friendly," were accompanied by reports of abuse, urinary and cerebellar toxicity, and fatal intoxications. Paradoxically, preclinical work has also identified rapid antidepressant-like effects mediated through glutamatergic and AMPA-receptor signaling, mirroring ketamine.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
antagonist
antagonist
reuptake inhibitor
agonist
reuptake inhibitor
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.